Molecular structure of Veliparib, CAS Number: 912444-00-9
Veliparib (CAS 912444-00-9)
See product citations (3)
Alternate Names:
ABT 888; 2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide
Application:
Veliparib is a potent PARP-1/-2 inhibitor shown to potentiate DNA damaging agents
CAS Number:
912444-00-9
Molecular Weight:
244.29
Molecular Formula:
C13H16N4O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Veliparib, a potent inhibitor of the poly(ADP-ribose) polymerase (PARP) enzymes PARP-1 and PARP-2, is extensively studied within the realm of molecular biology and oncology research for its role in enhancing the efficacy of DNA-damaging agents, such as temozolomide (TMZ). The mechanism of action of veliparib involves the inhibition of PARP enzymes, which play a critical role in the repair of single-strand DNA breaks. By inhibiting these enzymes, veliparib prevents the repair of DNA damage in cancer cells, thereby potentiating the cytotoxic effects of agents like TMZ.
Veliparib (CAS 912444-00-9) References
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. | Murai, J., et al. 2012. Cancer Res. 72: 5588-99. PMID: 23118055
- Profile of veliparib and its potential in the treatment of solid tumors. | Wagner, LM. 2015. Onco Targets Ther. 8: 1931-9. PMID: 26251615
- PARP Inhibitors in Ovarian Cancer. | Mittica, G., et al. 2018. Recent Pat Anticancer Drug Discov. 13: 392-410. PMID: 29512470
- PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. | Yin, L., et al. 2018. J Exp Clin Cancer Res. 37: 153. PMID: 30012171
- Veliparib: a new therapeutic option in ovarian cancer? | Ghisoni, E., et al. 2019. Future Oncol. 15: 1975-1987. PMID: 31074636
- Veliparib for advanced ovarian cancer. | Burki, TK. 2019. Lancet Oncol. 20: e616. PMID: 31587883
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. | Boussios, S., et al. 2020. Invest New Drugs. 38: 181-193. PMID: 31650446
- Veliparib overcomes multidrug resistance in liver cancer cells. | Chang, L., et al. 2020. Biochem Biophys Res Commun. 521: 596-602. PMID: 31679697
- The forefront of ovarian cancer therapy: update on PARP inhibitors. | Mirza, MR., et al. 2020. Ann Oncol. 31: 1148-1159. PMID: 32569725
- An Overview of PARP Inhibitors for the Treatment of Breast Cancer. | Cortesi, L., et al. 2021. Target Oncol. 16: 255-282. PMID: 33710534
- Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma. | Buck, J., et al. 2021. Front Mol Biosci. 8: 633344. PMID: 33996894
- Veliparib for the treatment of solid malignancies. | George, RR., et al. 2022. J Oncol Pharm Pract. 28: 924-934. PMID: 35037770
- CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. | You, B., et al. 2023. J Clin Oncol. 41: 107-116. PMID: 35867965
Inhibitor of:
β-defensin 28, β-defensin 30, β-defensin 37, 4930547N16Rik, AK7, ART2B, ASCC2, ATAD5, BABAM1, BC066135, BC068157, BRAT1, BRCAA1, C12orf32, C17orf53, C18orf37, C1orf55, C20orf196, C9orf102, C9orf119, CCDC98, DCAR1, ELOF1, FAAP100, FAN, FBXW22, Fhit, GTBP, H2-10, hCAP-D3, HELIC2, hMLH3, MND1, Npl1, OVCA1, PALB2, PAMR1, PAR4, Paraxis, PARN, PARP L, PARP S, PARP-1, PARP-10, PARP-11, PARP-12, PARP-14, PARP-16, PARP-2, PARP-6, PARP-7, PARP-8, PARP-9, Pem, PHAPI2, PMS1, PRK2, PRP19, PSG9, Rad26, RBBP1, RECA-1, RNF146, SNM1A, TDE1, TDP1, TDP2, TdTIF1 (DNTTIP1), TIMP-1, TRABID, USP17L5, V1RH17, XPV, XRCC2, XRCC3, XRCC4, and ZRANB3.Activator of:
4930547N16Rik, ARH3, DNA pol θ, DNAH5, FIGNL1, pADPr, PARG, PARP-4, PGBD5, Rad18, RAD51AP2, Rad51B, Spartan, ST7, TP53TG5, TTI1, USP1, and XRCC3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Veliparib, 5 mg | sc-394457A | 5 mg | $182.00 | |||
Veliparib, 10 mg | sc-394457 | 10 mg | $275.00 | |||
Veliparib, 50 mg | sc-394457B | 50 mg | $726.00 |